Amgen presented landmark clinical trial data indicating its cholesterol-lowering drug Repatha reduces risk of major cardiovascular events in patients without prior cardiovascular disease. The study supports a broader indication for primary prevention, proactively addressing high LDL cholesterol levels. This positive outcome could accelerate Repatha’s market penetration and strengthen its profile amid renewed interest in PCSK9 inhibitors to lower cardiovascular morbidity and mortality.